Coronavirus / COVID

Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.

A study of patients hospitalized with COVID-19 pneumonia found namilumab, but not infliximab, significantly reduced inflammation and CRP concentration.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

Children in the United States will be able to avoid potentially millions of hours of at-home quarantining under a testing program unveiled by the CDC today.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.

A clinical trial of 8 sub-Saharan African countries will be the first to study the efficacy of mRNA COVID-19 vaccination in people living with HIV.

Patients with severe COVID-19 who received high-flow oxygen therapy were less likely to need mechanical ventilation and had a shorter time to clinical recovery, investigators in Colombia found.

The company believes the pill should work against the Omicron variant.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Here is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Health officials in Mississippi reported a sharp increase in COVID-19-associated deaths among pregnant women during after the Delta variant became predominant.

The FDA granted an Emergency Use Authorization to Evusheld, AstraZeneca’s long-acting monoclonal antibodies for COVID-19 prevention in high-risk individuals.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

New research reveals that women who test positive for COVID-19 at the time they give birth pass along antibodies in breast milk, protecting their newborns from infection

Parents who were themselves vaccinated against COVID-19 were more likely to vaccinate their children than parents who were not, yet even vaccinated parents showed some hesitancy.

High-titer convalescent plasma administered to high-risk outpatients within a week of symptom onset didn’t prevent disease progression, according to a new study.

The recall involves 2 lots of 100 mg of remdesivir for injection to the user level.

The agency said the 2 monoclonal antibodies could be used to treat mild to moderate COVID-19 in all younger pediatric patients, including newborns.

A new study looked at COVID-19 related stressors and healthcare experiences, like facing discrimination, fear of perinatal infection, birth preparedness stress, telehealth prenatal care, disruptions to prenatal care, birth satisfaction, and duration of hospitalization and how these factors affected vaccination.